Istituto Di Ricerche Farmacologiche Mario Negri

At Istituto Di Ricerche Farmacologiche Mario Negri, clinical trials in immune system diseases and pathological kidney conditions focus on major forms of glomerular disease, including IgA nephropathy, membranous nephropathy, and complement-mediated kidney disease. These studies are designed to test new therapies that may reduce proteinuria, improve kidney outcomes, and better control disease activity.

• Research on IgA nephropathy and related progressive kidney disorders
• Studies in membranous nephropathy and relapsing nephrotic syndrome
• Trials targeting complement-driven renal disease to improve disease control

The site’s work reflects a strong emphasis on therapies aimed at slowing kidney damage and improving long-term renal function in patients with complex immune-related kidney diseases.

Several trials at the Centro Clinico Aldo e Cele Daccò are centered on lowering proteinuria and protecting kidney function in people with chronic kidney disease. The research includes evaluation of new treatment options for non-diabetic chronic kidney disease and conditions where excess urinary protein signals ongoing kidney injury.

• Testing treatments intended to reduce proteinuria
• Evaluating approaches to delay kidney disease progression
• Studying renal protection in chronic kidney disease

These studies aim to identify therapies that may preserve kidney function and offer better disease control for patients at risk of worsening renal outcomes.

Work in female urogenital diseases and broader renal disorders includes multiple trials in primary membranous nephropathy, idiopathic nephrotic syndrome, and rituximab-resistant or rituximab-dependent disease. The main purpose is to assess whether newer therapies can induce remission and support patients who have limited response to earlier treatment.

• Research in primary membranous nephropathy
• Studies in nephrotic syndrome with persistent protein loss
• Testing rescue therapies for patients with difficult-to-treat disease

These trials are important for understanding how to improve treatment effectiveness in patients with relapsing or treatment-resistant kidney disease.

Another major area of research at this laboratory and testing facility is IgA nephropathy and closely related glomerular diseases, including complement 3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis. The trials are focused on evaluating whether new therapies can reduce kidney inflammation, lower proteinuria, and slow loss of kidney function.

• Clinical studies in IgA nephropathy
• Research on C3 glomerulopathy and IC-MPGN
• Testing treatments that may preserve renal function

Overall, the site is contributing to the development of more targeted options for patients with immune-driven kidney diseases that can gradually damage the kidneys over time.

Trials in nutritional and metabolic diseases at Istituto Di Ricerche Farmacologiche Mario Negri also explore therapies that may support kidney health in patients with progressive renal impairment. The research includes studies of treatment combinations and novel agents intended to improve kidney function and delay disease worsening.

• Evaluating new options for kidney protection
• Studying therapies that may slow decline in eGFR
• Assessing treatment strategies for complex chronic renal disease

These investigations broaden the site’s kidney-focused portfolio by looking at ways to manage disease progression through innovative medical approaches.